cyrilzakka/clinical-trials huggingface dataset:
Food Intake Decisions

Functional Magnetic resonance study on the effect of cognitive context variables on the perception and valuation of food odorants and flavor. The study is composed of two experiments; in a first experiment we address the question of how valuation of food odors are modulated by 3 cognitive conditions (indulgence, healthy, and neutral). Food odors are delivered using a custom-made olfactometer. Here we hypothesize that cognitive regulation can modulate the primary sensory processing of food odors. We expect that cortical regions related with valuation and cognitive regulation such as the ventromedial prefrontal cortex and the dorsolateral prefrontal cortex operate the modulation of primary olfactory cortex and amygdala. In a second experiment, we aim to reveal the brain areas involved in integrating food color cues with odor and taste stimuli. Here we hypothesize that color cues are capable of biasing flavor attributes of food (flavor intensity), and that this bias occurs at different cortical areas commonly associate with multisensory integration such as the orbitofrontal cortex, insula, amygdala and hippocampus.


Eligibility Criteria:
Inclusion Criteria:

* healthy or Prader-Willi
* right handed

Exclusion Criteria:

* Nursing or pregnant women
* undergoing medical treatment
* Having known olfactory disorder
* neurological or psychiatric history
* all pertinent conditions according to the use of magnetic resonance imaging.
* anosmia (partial/total)
* neurological, psychological or other disease
GLP-1 on Non-ST-Segment Elevation Myocardial Infarction

The investigators planned to evaluate the effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction (NSTEMI).

Patients with non-ST-segment elevation myocardial infarction (NSTEMI) are a heterogeneous group with respect to the risk of having a major adverse cardiac event (MACE). Elevation of blood glucose is a common metabolic disorder among patients with acute myocardial infarction (AMI) and is associated with adverse prognosis. Glucagon-like peptide-1 (GLP-1) is an incretin hormone that regulates plasma glucose. GLP-1 analogues have significant cardiovascular protective effects in patients with AMI. GLP-1 may have antioxidant and anti-inflammatory properties, and protect endothelial function. Studies in conscious, chronically instrumented dogs demonstrated that GLP-1 infusion increases insulin sensitivity and myocardial glucose uptake in postischemic contractile dysfunction and dilated cardiomyopathy. Liraglutide, a GLP-1 analogue, was reported to reduce cardiac rupture and infarct size and improve cardiac output in normal and diabetic mice. Continuous infusion of GLP-1 (1.5 pmol/kg/min) has been shown to improve functional recovery in patients with AMI complicated by decreased left ventricular function GLP-1 could protect against ischemia-reperfusion injury and improve cardiac function in patients with acute ST-segment elevation myocardial infarction. However, the effects of GLP-1 on NSTEMI patients remain unclear. The aim of this study was to evaluate the effects of liraglutide on left ventricular function in patients with NSTEMI.

Eligibility Criteria:
Inclusion Criteria:

non-ST-segment elevation myocardial infarction (NSTEMI )

Exclusion Criteria:

1. unconscious at presentation
2. had ST-segment elevation acute myocardial infarction
3. NSTEMI requiring emergency percutaneous coronary angiography
4. valvular heart disease
5. cardiogenic shock
6. hypoglycaemia
7. diabetic ketoacidosis
8. had a history of myocardial infarction
9. stent implantation
10. renal insufficiency
11. had previously undergone coronary artery bypass surgery.
Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet

Evaluate the efficacy and safety of a 16-week course of Humira (adalimumab) compared to placebo in adults with chronic plaque psoriasis of the hands and/or feet and the sustainability of response for 12 additional weeks.


Eligibility Criteria:
Inclusion Criteria:

* Adult with Diagnosis of chronic plaque psoriasis of the Hands and Feet for at least 6 months, with a PGA \>/=3 and candidates for systemic therapy;
* Patients in good general health
* Able to self-administer injections
* Negative chest x-ray (CXR) and purified protein derivative (PPD) test, unless willing to start anti-tuberculosis (TB) prophylaxis

Exclusion Criteria:

* Previous treatment with HUMIRA®
* Required mediation stability or washouts for: systemic corticosteroids (28 days), other investigational agent, other systemic therapies for psoriasis, ultraviolet B (UVB), psoralen with UVA (PUVA)
* Other active skin diseases or skin infections
* Diagnosis of palmoplantar pustulosis; erythrodermic psoriasis, pustular psoriasis, medication-induced or exacerbated psoriasis or new onset of guttate psoriasis
* Evidence of dysplasia or history of malignancy (Other than a successfully treated non-metastatic cutaneous squamous cell, basal cell carcinoma or localized carcinoma in situ of the cervix);
* History of listeriosis, histoplasmosis, chronic or active Hepatitis B infection, human immunodeficiency virus (HIV) infection, immunodeficiency syndrome, chronic recurring infections or active tuberculosis (TB);
* History of moderate to severe congestive heart failure,
* Recent cerebrovascular accident and any other condition which, in the opinion of the investigator, would put the subject at risk;
* History of central nervous system (CNS) demyelinating disease or neurologic symptoms suggestive of CNS demyelinating disease;
* History of clinically significant drug or alcohol abuse in the last 12 months;
* Infection(s) requiring treatment with intravenous (IV) antibiotics, IV antivirals, or IV antifungals within 30 days prior to Baseline or oral antibiotics, oral antivirals, or oral antifungals within 14 days prior to Baseline;
* Known hypersensitivity to the excipients of HUMIRA® as stated in the label;
* Female subjects who are pregnant or breast-feeding or considering becoming pregnant during the study.
* Prior exposure to Tysabri® (natalizumab)
Surveillance for Multifocal GGNs

This study is a single-arm, multi-center, phase III trial conducted under the Eastern Cooperative Thoracic Oncoloy Project (ECTOP) with the identification number ECTOP-1021. The primary objective of the study is to assess the overall survival of patients with multifocal ground-glass opacities by employing a active surveillance approach rather than opting for surgical resection.

The trial aims to confirm the hypotheses that delaying surgery until GGO nodules exhibit progression or meet certain criteria offers a prognosis equivalent to those undergoing immediate surgical resection, potentially allowing many of these patients to avoid surgery altogether.

Eligibility Criteria:
Inclusion criteria Patients eligible for enrollment in the study are required to meet all the following criteria.

1. Demonstrates the following on thin-section computed tomography (TSCT) scan:

   1. Presence of three or more GGNs (bilateral lesions are permitted).
   2. All lesions have remained stable without regression or enlargement for at least 3 months.
   3. The dominant lesion (the lesion with the largest maximum tumor diameter) has a maximum tumor diameter \>=0.6cm and \<=2cm.
   4. CTR \<=0.25 in all lesions.
   5. No lymph node with a diameter \>1cm in the mediastinal view.
   6. Not adjacent to the pleura in dominant lesion and no sign of pleural retraction in any lesions.
2. Aged 18-75 years.
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
4. Has not previously undergo any anti-tumor drug or radiation therapy.
5. Written informed consent.

Exclusion criteria Patients will be excluded if they meet any of the following criteria.

1. History of any prior malignancies within the past 5 years.
2. History of lung surgery.
3. History of interstitial pneumonia, pulmonary fibrosis or other severe pulmonary diseases.
4. Presence of severe or uncontrolled diseases that may possibly reduce the 10-year life expectancy.
Translation and Validation of the Visual Analysis of Swallowing Efficiency and Safety Into European Portuguese

The goal of this observational study is to translate and validate to European Portuguese "Visual Analysis of Swallowing Efficiency and Safety - VASES".


Eligibility Criteria:
Inclusion Criteria:

* Patient's FEES recording that allowed good visualization of the pharynx and larynx;
* FEES recording from patients after head and neck surgery who had structural alterations but still did not interfere with a clear visualization of the residues.
* Patient's tracheostomized or under enteral nutrition.

Exclusion Criteria:

* Under 18 years of age
Adaptive and Trained Immunity in the Pathogenesis of IgG4-Related Disease

Enquire involvement of trained immunity in the pathogenesis of IgG4RD

Enquire involvement of trained immunity in the pathogenesis of IgG4RD using primary macrophages and co-cultures with patient derived fibroblasts. The investigators will first assess whether macrophages from patients are trained compared to macrophages of healthy controls and then challenge them with IgG from IgG4RD patients to evaluate the functional effects on cultivated fibroblasts.

Eligibility Criteria:
Inclusion Criteria:

Patients:

* Adult subjects \> or = 18 years of age
* Subjects capable of providing informed consent
* Active IgG4-RD based on the IgG4-related disease activity index
* Fulfillment of the 2019 ACR/EULAR Classification Criteria for IgG4RD

Healthy Controls:

* Adult subjects \> or = 18 years of age
* Subjects capable of providing informed consent

Exclusion Criteria:

Patients and healthy controls:

* Subjects \< 18 years of age
* Pregnant women
* Comorbidities (other ongoing active autoimmune diseases, ongoing cancer, ongoing infections)
* Ongoing immunosuppressive therapy
Randomized Trial Assessing the Effectiveness of a Pharmacist-Delivered Program for Smoking Cessation

This randomized trial compared the effectiveness of a three session pharmacist-delivered group program for smoking versus one 5 to 10 minute standard care session delivered over the telephone on 7-day point prevalence quit rates. Participants in both groups were offered their choice of bupropion IR or nicotine patch at no cost. At 6 months after the established quit date, self-reported cessation was biochemically verified using tests for urinary cotinine.


Eligibility Criteria:
Inclusion Criteria:

* Smoked one or more cigarettes daily for 7 days
* Somewhat ready to quit in the next 2 weeks (4 or more on a 10- point scale)
* Willing and capable of attending three scheduled sessions at the clinic
* Interested in participating in the study

Exclusion Criteria:

* Planned to leave the area in the next 6 months
* Used pharmacotherapy for smoking cessation in the last 30 days
* Used other forms of tobacco in the last 30 days
* Schizophrenia
* Prior participation
The Effect of Coffee and Hot Water on Gastroıntestınal Functıons

The aim of this study is to examine the effects of coffee and hot water consumption on gastrointestinal system functions after cesarean section performed under general anesthesia. The study is in a randomized controlled experimental design.

The sample of the study consisted of 25 participants in the coffee group (Group 1), 26 participants in the hot water group (Group 2) and 27 participants in the control group (Group 3). After cesarean section, at the 4th, 8th and 12th hours of the operation, the first intervention group (coffee group) received 2 gr. granulated coffee, the second intervention group (hot water group) was given 100 ml of 50-60 C0 sugar-free hot water, the third group (control group) was given no intervention other than routine applications.

Objective: The aim of this study is to examine the effects of coffee and hot water consumption on gastrointestinal system functions after cesarean section performed under general anesthesia.

Materials and Methods: The study is in a randomized controlled experimental design. Patients who had an uncomplicated cesarean section under general anesthesia, were older than 18 years of age, completed the 37th week of pregnancy, did not have any gastrointestinal system disease that could affect the results of the study, and did not use drugs, and who could understand and speak Turkish were included in the study. The sample of the study consisted of 25 participants in the coffee group (Group 1), 26 participants in the hot water group (Group 2) and 27 participants in the control group (Group 3). After cesarean section, at the 4th, 8th and 12th hours of the operation, the first intervention group (coffee group) received 2 gr. granulated coffee, the second intervention group (hot water group) was given 100 ml of 50-60 C0 sugar-free hot water, the third group (control group) was given no intervention other than routine applications.

Eligibility Criteria:
Inclusion Criteria:

* Cesarean section performed by the physician determined in the research
* Over 18 years old,
* Completing the 37. gestational week,
* Do not have any gastrointestinal system disease that may affect the results of the research and do not use drugs,
* Able to understand and speak Turkish,
* Women who voluntarily participated in the study

Exclusion Criteria:

* Cesarean section performed by a different physician than the physician determined in the study.
* Younger than 18,
* Not completing the 37.gestational week
* Having any gastrointestinal system disease that may affect the research results and using medication
* Can't understand or speak Turkish.
OSV-IRM - Volunteer MRI Sequence Optimization

Optimization of magnetic resonance imaging (MRI) protocols on healthy volunteers and voluntary patients.

In MRI, a large number of technical parameters (sequence, parameters in sequence, antenna, reconstruction method, etc.) can be changed to optimize the diagnostic quality of the exam. Some optimizations can be performed on participants healthy volunteers, others need to be carried out on images pathological and acquired in voluntary patients.

An inclusion visit is planned to verify the criteria for selection, then an imaging visit to perform the MRI examination.

The imaging visit can take place at the end of the inclusion visit and until the following 15 days. For healthy volunteers, the visits are organized according to their availability. For patients, on the other hand, participation in the research will depend on the programming of the MRI within the framework care.

This is a single-center prospective study carried out at two sites in the Rennes University Hospital.

Eligibility Criteria:
Inclusion Criteria:

* Criteria common to all participants:

  * Minor or major subject
  * Affiliated, himself or through his parents if he is a minor, to a a social security scheme
  * Having given their free, informed and written consent, and/or which the free, informed and written consent of the holder(s) parental authority has been obtained for minors

Specific criteria for healthy volunteers:

o No medical or surgical history related to the anatomical area(s) scanned

Specific criteria for voluntary patients:

o Indication for an MRI exam as part of its management

Exclusion Criteria:

* - Contraindication to an MRI (pacemaker or pacemaker, neurostimulator, intra-orbital metal body, vascular clip ferromagnetic)
* Pregnancy
* Legal protection measure for adults in progress (safeguard of justice, guardianship, curatorship) or subject deprived of liberty
Lifestyle Intervention and Physical Capacity in Patients With Morbid Obesity

Lifestyle intervention and physical capacity in patients with morbid Obesity (LEICO)

It is still uncertainty about which is the most effective lifestyle treatment to reducing body weight and increased quality of life. Increased physical capacity and muscle mass lead to increased energy expenditure, thus explaining parts of the difference in weight loss achieved after lifestyle treatment. However, literature in this area is limited and need better documentation of how, and to what extent increased physical capacity can affect the effect of lifestyle treatment offered to patients in the health service.

Eligibility Criteria:
Inclusion Criteria:

* Treatment morbidly obese patients (BMI ≥ 40 kg/m2 or BMI 35 to 39.9 kg/m2 with ≥ 1 co morbidity) attending the Vestfold Hospital Trust.

Exclusion Criteria:

* Uncompensated heart failure
* Recent myocardial infarction or stroke (\<½ years)
* Severe arrhythmia or heart failure
* Unstable angina pectoris
* Renal failure
* Severe eating disorders
* Active substance abuse
Vitamin D Intervention and Associated Changes in the Gut Microbiome and Vitamin D Levels in Healthy Adults

Although dietary vitamin D supplementation has been used in the clinical setting for decades, the effect of supplementary vitamin D consumption on the structure of the microbiome has not been studied in humans in fine scale or with concomitant adjustment for dietary intake. Understanding the interaction of vitamin D with the microbiome in humans could lead to important advancements in the understanding of how vitamin D together with diet impacts the microbiome composition, and ultimately, risk of EOCRC. This study has the potential to lay the ground work for an adjunctive therapy to manipulate the microbiome to reduce risk of EOCRC. This proposed study is designed to evaluate the effect of vitamin D supplementation on the normal structure of the microbiome and data will not be used to diagnose, prevent, cure or treat disease.


Eligibility Criteria:
Inclusion Criteria:

* Adult 18 years or older

Exclusion Criteria:

* Women who are currently pregnant or breastfeeding
* Use of antibiotics within the last 2 weeks
* Use of supplementary vitamin D within the last month
* Self-reported, pre-existing history of inflammatory bowel disease, heart disease or diabetes
* Students under 18
* Tanning/sun exposure \> 60 min at a time in last 4 weeks
* No phenobarbital, carbamazepine, spironolactone chronic therapy; or steroid use within the last 2 weeks
* Severe allergy to ingredients found in supplements
Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

This is a phase IIIb randomised, double-blind, double-dummy, multicentre, parallel group, 24 week study to assess the efficacy and safety of Glycopyrronium/Formoterol Fumarate (GFF) fixed-dose combination 7.2/4.8 μg 2 inhalations twice daily compared to Umeclidinium/Vilanterol (UV) 62.5/25 μg fixed-dose combination 1 inhalation once daily in Patients with moderate to very severe COPD.


Eligibility Criteria:
Inclusion criteria:

* Age 40-95 years at screening
* Current or former smoker with a history of at least 10 pack-years of cigarette smoking
* Current clinical diagnosis of COPD, with COPD symptoms \> 1 year prior to screening, as defined by GOLD criteria or other current guidelines
* COPD Severity defined by FEV1/FVC ratio \<0.70 and FEV1 \<80% of predicted normal value at screening and at randomisation
* COPD treatment with rescue medication only, or stable dose of maintenance monotherapy (LAMA, LABA or ICS), or stable dose of double maintenance therapy (LAMA/LABA or ICS/LABA), for one month prior to screening
* COPD Assessment Test (CAT) score ≥10 at randomisation
* Documentation of a chest x-ray (as per local practice) or computed tomography (CT) within 6 months prior to screening, with no clinically significant pulmonary abnormalities other than related to COPD

Exclusion criteria:

* Respiratory disease other than COPD, including:
* Current diagnosis of asthma
* Alpha-1 Antitrypsin Deficiency as the cause of COPD
* Other respiratory disorders and conditions as listed in the protocol
* Severe COPD exacerbation (resulting in hospitalisation) not resolved within 8 weeks prior to screening, or moderate exacerbation not resolved within 4 weeks, or during screening
* Pneumonia or lower respiratory tract infection that required antibiotics within 8 weeks prior to screening, or during screening.
* Significant diseases or conditions other than COPD which may put the patient at risk, or influence the results of the study or the patient's ability to participate, including cardiac disease, advanced renal disease, and cancer that has not been in complete remission for at least 5 years.
* Patients who have needed additions or alterations to their usual maintenance therapy for COPD due to worsening symptoms within 1 month prior to and during screening
* Treatment with depot corticosteroids within 6 weeks, or other systemic corticosteroids within 4 weeks, prior to screening. (Patients maintained on an equivalent of 5 mg prednisone per day for at least 3 months prior to screening are allowed.)
Cortical Stimulation by Direct Current for the Treatment of Chronic Pain : Pilot-study of a Stimulation Device at Home

The purpose of this study is to confirm the analgesic effect of tDCS in neuropathic chronic pain, to estimate the importance and the duration of this effect, and to improve its efficiency by the use at home.

It is established that the repetition of the sessions of cortical stimulation over a week improves their analgesic efficacy. However, this effect does not exceed a few weeks and is much lower than that of the stimulation implanted surgically. Implanted stimulation operates periodically, several times a day, and this "repetition of doses ", akin to the regular taking of a medicine, may explain its longer efficacy for pain relief which, may extend over several years (André-Obadia and al 2014).

No study at this date has estimated the long-term effect of non-invasive stimulation when is also periodically repeated on a daily basis, over several weeks.


Eligibility Criteria:
Inclusion Criteria :

* Patients from 18 to 80 years old, men or women, suffering pharmaco-resistant neuropathic chronic pain for more than one year; NVS \> 2 during the week S0) unilateral pharmacoresistant, whose analgesic treatment is stable for at least 1 month.
* Patients whose pharmacoresistance leads their referent doctor to consider non-pharmacological therapeutic alternatives and begin a presurgical assessment.
* Patients having an operational Internet connection. The patient or one person of its circle of acquaintances will have to be able to connect on the Internet and to reach by this way the system of relocated stimulation ("The Cloud").
* Patients having shown pain relief to a single- or whole-week sessions of tDCS are not excluded from potential recruitment for this study.
* Patients having a social security cover.
* Patients having given their written consent.

Exclusion Criteria :

* History
* of addiction to drugs,
* of epilepsy.
* Présence of an intra-cranial ferromagnetic equipment or of an implanted stimulation device (e.g. stimulating, central grey pacemaker, stimulation of the basal ganglia or of the vagus nerve).
* Introduction of a new analgesic treatment for less than a month.
* Lack of a effective contraception for all the duration of the study for the patients old enough to procreate.

(No limitation in the inclusion of male patients old enough to procreate).

* Patient under legal protective measure.
* Pregnant women and nursing mothers
Bladder Cancer Longitudinal Biorepository for Development of Novel Therapeutics/Biomarkers

The purpose of this study is to create a registry, which is a "bank" of information about patients who have had similar medical conditions and treatments. The registry will be used by researchers to learn more about long term outcome of patients with bladder cancer, how bladder cancer tissues are related to tumor development, recurrence and survival.


Eligibility Criteria:
Inclusion Criteria:

* Patients who present to clinic with presumed bladder cancer or have a diagnosis of bladder cancer are eligible to participate
* Patients can participate in any additional research studies during the patients' participation within this protocol.

Exclusion Criteria:

* Patients who do not have presumed bladder cancer will not be eligible